Clinical
Trials
If you are a patient or health care provider who would like more information about a clinical trial, please contact our research team.
If you are a patient or health care provider who would like more information about a clinical trial, please contact our research team.
At BeiGene, we’re committed to bringing patients worldwide potential treatment options. We are currently recruiting clinical trials across areas including lymphoma, liver cancers, lung cancers, gastric cancers, breast cancers, and more.
-
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) (ASPEN)
Condition:
Waldenström's Macroglobulinemia
Molecule:BGB-3111
-
Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC
Condition:
Hepatocellular Carcinoma (HCC)
Molecule:Tislelizumab
-
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous NSCLC
Condition:
Lung Cancer
Molecule:Tislelizumab
-
A Study Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
Condition:
Lung Cancer
Molecule:Tislelizumab
-
Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer
Condition:
Solid Tumor
Molecule:Pamiparib
-
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia (ALPINE)
Condition:
Lymphocytic Lymphoma, Lymphocytic Leukemia
Molecule:Zanubrutinib
-
Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
Condition:
Hepatocellular Carcinoma (HCC)
Molecule:Tislelizumab
-
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
Condition:
Breast Cancer, Ovarian Cancer
Molecule:Pamiparib
-
Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With NSCLC
Condition:
Lung Cancer
Molecule:Tislelizumab
-
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Condition:
Esophageal Squamous Cell Carcinoma (ESCC)
Molecule:Tislelizumab
Clinical trials are an important part of our research and development efforts and help make possible access to safe and potentially life-saving treatments.
This list includes trials with the following recruitment statuses: recruiting, enrolling by invitation, study start-up, not yet recruiting, and active/not recruiting.